AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments. AbbVie and Neomorph have announced a collaboration ...